Japan-based Kobayashi Pharmaceutical has reportedly initiated a product recall in the Chinese market for its cholesterol-lowering pills containing red yeast rice. This decision follows the discovery of “unintended elements” in the raw materials and reports of kidney disease among some users. Additionally, two other products with similar formulations have also been withdrawn from circulation.
Red yeast rice, derived from the fermentation of the mold Monascus purpureus, contains high levels of Monacolin K, a compound effective in lowering cholesterol and commonly found in various statin medications. However, its use is not without risks, including potential damage to muscles, kidneys, and liver. Furthermore, certain red yeast rice products have been identified to contain a contaminant known as citrinin, which poses a risk of kidney failure, according to information from the Mayo Clinic.
Kobayashi currently manufactures only 20% of its raw materials for red yeast rice products in-house, sourcing the remainder from Japan and Taiwan. The company’s products are predominantly sold through popular e-commerce platforms, including Tmall, Pinduoduo, and JD.com.- Flcube.com
